Actively Recruiting
Enabling Women with Parkinson's Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms
Led by University Hospital, Grenoble · Updated on 2025-03-25
100
Participants Needed
4
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Forty percent of people living worldwide with Parkinson's disease (PD) are women. Twenty percent of patients have PD onset under the age of 60 years, a time when women may encounter significant caregiving responsibilities along with occupational and other competing demands. Studies with surveys of women with PD (WwPD) have reported worsening of PDrelated symptoms especially in the week prior and the week of menses. However, prospective evidence is scarce and clinical guidelines to manage this issue do not exist. As a result, care is either non-existent or fragmented. The investigators propose a French multicentre prospective pilot study to capture changes in PD symptoms in relation to the stages of the menstrual cycle aiming at reducing hormonal related worsening in PD symptoms through neurologist intervention and/or patient selfmanagement. Digital technology will remotely enable patient reported outcome (PRO) tracking through the My Moves Matter app changes in PD symptoms during several months. This information will then help neurologists to customize treatment. Changes in motor symptoms will also be highlighted by tracking through the use of a wearable device (PDMonitor) to objectively detect motor changes together with the app. This will further support the reliability of the app. This study will provide evidence for the impact of the menstrual cycle on PD and help neurologists and patients to better manage PD symptoms related to these hormonal changes.
CONDITIONS
Official Title
Enabling Women with Parkinson's Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Non-menopausal women
- Diagnosis of Parkinson's disease according to MDS criteria with symptom onset at least two years ago
- Age between 18 and 56 years
- Stable Parkinson's medication regimen for at least two months without planned changes in the next three months
- Use or non-use of oral contraceptive pills or intrauterine devices
You will not qualify if you...
- Post-menopausal women with Parkinson's disease
- Conditions preventing safe or successful study participation (e.g., dementia, severe depression)
- Unable to give informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
CHU Grenoble Alpes
Grenoble, Grenoble, France
Actively Recruiting
2
CHU Nantes Hôpital Laennec
Nantes, France, 44000
Actively Recruiting
3
CHU Rennes -Site Pontchaillou
Rennes, France, 35000
Actively Recruiting
4
Chu Toulouse
Toulouse, France, 31000
Actively Recruiting
Research Team
E
Elena MORO
CONTACT
P
PIERRE PELISSIER
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here